RecruitingMultiple Myeloma
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Eligible age
18+ yrs
Accepts
All genders
Locations
27 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
You may qualify if…
- ✓ Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria.
- ✓ Received at least 4 classes of MM treatment \[including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, anti-BCMA therapy, and at least 3 prior lines of therapy (LOT).
- ✓ Documented disease progression during or after their last anti-myeloma regimen as per IMWG 2016 criteria.
- ✓ Participants must have measurable disease during screening.
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
You may not qualify if…
- ✕ Active or history of central nervous system involvement with MM.
- ✕ Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis. Participants with severe infection, severe sepsis or bacteremia in the last 28 days prior to leukapheresis are excluded.
- ✕ Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis.
- ✕ Other protocol-defined Inclusion/Exclusion criteria apply.
Where it's recruiting
Source: ClinicalTrials.gov · NCT06297226 · last updated 2026-05-28